NORTH AMERICA OPIOID INDUCED CONSTIPATION DRUG MARKET FORECAST 2017-2025
KEY FINDINGS
The North America opioid induced constipation drug market is expected to be the fastest growing market during the forecast period of 2017-2025 with an expected CAGR growth of 5.72%. The revenue generated by the market is expected to increase from $840.4 million in 2016 and reach $1382.73 million by 2025.
MARKET INSIGHTS
The North American OIC drug market is segmented on the basis of the type of prescription and the type of drug. The prescription type market is further divided into prescribed drugs such as branded and generic drugs and the over the counter drugs which do not require any doctor prescription. The market on the type of drug can be further segmented into methyl naltrexone bromide, lubiprostone, naloxegol and pipeline drugs. The increase in healthcare spending, technological advancement in cardiology and growing life style oriented diseases are aiding in the expansion of the market in this region.
COMPETITIVE INSIGHTS
Some of the major players in the market include
The North America opioid induced constipation drug market is expected to be the fastest growing market during the forecast period of 2017-2025 with an expected CAGR growth of 5.72%. The revenue generated by the market is expected to increase from $840.4 million in 2016 and reach $1382.73 million by 2025.
MARKET INSIGHTS
The North American OIC drug market is segmented on the basis of the type of prescription and the type of drug. The prescription type market is further divided into prescribed drugs such as branded and generic drugs and the over the counter drugs which do not require any doctor prescription. The market on the type of drug can be further segmented into methyl naltrexone bromide, lubiprostone, naloxegol and pipeline drugs. The increase in healthcare spending, technological advancement in cardiology and growing life style oriented diseases are aiding in the expansion of the market in this region.
COMPETITIVE INSIGHTS
Some of the major players in the market include
- Ironwood Pharmaceuticals Inc
- Pfizer
- Progenics Pharmaceuticals Inc
- Allergan PLC
- others
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
4. MARKET OVERVIEW
4.1. MARKET DEFINITION
4.2. KEY MARKET INSIGHTS
4.3. ATTRACTIVE INVESTMENT SCENARIO
4.4. POSITIONING OF KEY CIC DRUGS MANUFACTURERS IN THE MARKET
4.5. MARKET DRIVERS
4.5.1. RISING USE OF OPIOID
4.5.2. INCREASING GERIATRIC POPULATION
4.5.3. INCREASING OPIOIDS PRESCRIPTION IN NORTH AMERICA
4.5.4. EASY AVAILABILITY OF IMPROVED AND EFFECTIVE OIC DRUGS
4.6. RESTRAINTS
4.6.1. RESEARCH ON PAIN AND NEXT GENERATION ANALGESICS
4.6.2. SIDE EFFECTS OF OIC DRUGS
4.6.3. UNAWARENESS AND IGNORANCE AMONG PATIENTS
4.7. OPPORTUNITY
4.7.1. INCREASING USE OF OPIOIDS
4.8. CHALLENGES
4.8.1. LARGE NUMBER OF CONSIDERATIONS WHILE USING OPIOIDS
5. NORTH AMERICA OIC DRUG MARKET BY DRUG TYPE 2017-2025 ($ MILLION)
5.1. OVERVIEW
5.1.1. METHYL NALTREXONE BROMIDE
5.1.2. LUBIPROSTONE
5.1.3. NALOXEGOL
5.2. PIPELINE DRUG ANALYSIS: PHASE 3: NALDEMEDINE (YEAR OF LAUNCH TO 2022 $ MILLION)
5.3. PIPELINE DRUG ANALYSIS: PHASE 2: ALVIMOPAN, DOLCANATIDE (QUALITATIVE INFORMATION)
5.4. PIPELINE DRUG ANALYSIS: PHASE 3: ELOBIXIBAT (YEAR OF LAUNCH TO 2022 $ MILLION)
6. NORTH AMERICA CIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
6.1. PRESCRIBED DRUGS
6.1.1. BRANDED
6.1.2. GENERIC
6.2. OVER THE COUNTER DRUGS
7. KEY ANALYTICS
7.1. PORTERS FIVE FORCE MODEL
7.1.1. INTENSITY OF COMPETITIVE RIVALRYOMPETITION AMONG THE
7.1.2. BARGAINING POWER OF SUPPLIERS
7.1.3. BARGAINING POWER OF BUYERS
7.1.4. THREAT OF SUBSTITUTE PRODUCTS
7.1.5. THREAT OF NEW ENTRANTS
7.2. VENDOR LANDSCAPE
7.3. OPPORTUNITY MATRIX
8. NORTH AMERICA OIC DRUGS MARKET BY COUNTRIES 2017-2025 ($ MILLION)
8.1. US
8.2. CANADA
9. COMPANY PROFILE
9.1. IRONWOOD PHARMACEUTICALS INC
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. STRATEGIC MOVES
9.1.4. SCOT ANALYSIS
9.2. DAIICHI SANKYO CO LTD
9.2.1. OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. STRATEGIC MOVES
9.2.4. SCOT ANALYSIS
9.3. PFIZER
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. STRATEGIC MOVES
9.3.4. SCOT ANALYSIS
9.4. PROGENICS PHARMACEUTICALS INC
9.4.1. OVERVIEW
9.4.2. STRATEGIC MOVES
9.4.3. SCOT ANALYSIS
9.5. SHIONOGI & CO., LTD.
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. STRATEGIC MOVES
9.5.4. SCOT ANALYSIS
9.6. ALLERGAN PLC
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. STRATEGIC MOVES
9.6.4. SCOT ANALYSIS
9.7. NEKTAR THERAPEUTICS
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. STRATEGIC MOVES
9.7.4. SCOT ANALYSIS
9.8. PURDUE PHARMA L.P.
9.8.1. OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. STRATEGIC MOVES
9.8.4. SCOT ANALYSIS
9.9. S.L.A. PHARMA AG
9.9.1. OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. SCOT ANALYSIS
9.10. MUNDIPHARMA INTERNATIONAL LIMITED
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. STRATEGIC MOVES
9.10.4. SCOT ANALYSIS
9.11. ONO PHARMACEUTICAL CO., LTD.
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. STRATEGIC MOVES
9.11.4. SCOT ANALYSIS
9.12. TAKEDA PHARMACEUTICAL COMPANY LIMITED
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. STRATEGIC MOVES
9.12.4. SCOT ANALYSIS
9.13. THERAVANCE BIOPHARMA INC
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. STRATEGIC MOVES
9.13.4. SCOT ANALYSIS
9.14. VALEANT PHARMACEUTICALS INTERNATIONAL
9.14.1. OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. STRATEGIC MOVES
9.14.4. SCOT ANALYSIS
9.15. COSMO PHARMACEUTICALS SA
9.15.1. OVERVIEW
9.15.2. PRODUCT PORTFOLIO
9.15.3. STRATEGIC MOVES
9.15.4. SCOT ANALYSIS
9.16. DAEWOONG PHARMACEUTICAL CO., LTD.
9.16.1. OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. STRATEGIC MOVES
9.16.4. SCOT ANALYSIS
9.17. C.B. FLEET COMPANY, INC.
9.17.1. OVERVIEW
9.17.2. PRODUCT PORTFOLIO
9.17.3. STRATEGIC MOVES
9.17.4. SCOT ANALYSIS
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
4. MARKET OVERVIEW
4.1. MARKET DEFINITION
4.2. KEY MARKET INSIGHTS
4.3. ATTRACTIVE INVESTMENT SCENARIO
4.4. POSITIONING OF KEY CIC DRUGS MANUFACTURERS IN THE MARKET
4.5. MARKET DRIVERS
4.5.1. RISING USE OF OPIOID
4.5.2. INCREASING GERIATRIC POPULATION
4.5.3. INCREASING OPIOIDS PRESCRIPTION IN NORTH AMERICA
4.5.4. EASY AVAILABILITY OF IMPROVED AND EFFECTIVE OIC DRUGS
4.6. RESTRAINTS
4.6.1. RESEARCH ON PAIN AND NEXT GENERATION ANALGESICS
4.6.2. SIDE EFFECTS OF OIC DRUGS
4.6.3. UNAWARENESS AND IGNORANCE AMONG PATIENTS
4.7. OPPORTUNITY
4.7.1. INCREASING USE OF OPIOIDS
4.8. CHALLENGES
4.8.1. LARGE NUMBER OF CONSIDERATIONS WHILE USING OPIOIDS
5. NORTH AMERICA OIC DRUG MARKET BY DRUG TYPE 2017-2025 ($ MILLION)
5.1. OVERVIEW
5.1.1. METHYL NALTREXONE BROMIDE
5.1.2. LUBIPROSTONE
5.1.3. NALOXEGOL
5.2. PIPELINE DRUG ANALYSIS: PHASE 3: NALDEMEDINE (YEAR OF LAUNCH TO 2022 $ MILLION)
5.3. PIPELINE DRUG ANALYSIS: PHASE 2: ALVIMOPAN, DOLCANATIDE (QUALITATIVE INFORMATION)
5.4. PIPELINE DRUG ANALYSIS: PHASE 3: ELOBIXIBAT (YEAR OF LAUNCH TO 2022 $ MILLION)
6. NORTH AMERICA CIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
6.1. PRESCRIBED DRUGS
6.1.1. BRANDED
6.1.2. GENERIC
6.2. OVER THE COUNTER DRUGS
7. KEY ANALYTICS
7.1. PORTERS FIVE FORCE MODEL
7.1.1. INTENSITY OF COMPETITIVE RIVALRYOMPETITION AMONG THE
7.1.2. BARGAINING POWER OF SUPPLIERS
7.1.3. BARGAINING POWER OF BUYERS
7.1.4. THREAT OF SUBSTITUTE PRODUCTS
7.1.5. THREAT OF NEW ENTRANTS
7.2. VENDOR LANDSCAPE
7.3. OPPORTUNITY MATRIX
8. NORTH AMERICA OIC DRUGS MARKET BY COUNTRIES 2017-2025 ($ MILLION)
8.1. US
8.2. CANADA
9. COMPANY PROFILE
9.1. IRONWOOD PHARMACEUTICALS INC
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. STRATEGIC MOVES
9.1.4. SCOT ANALYSIS
9.2. DAIICHI SANKYO CO LTD
9.2.1. OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. STRATEGIC MOVES
9.2.4. SCOT ANALYSIS
9.3. PFIZER
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. STRATEGIC MOVES
9.3.4. SCOT ANALYSIS
9.4. PROGENICS PHARMACEUTICALS INC
9.4.1. OVERVIEW
9.4.2. STRATEGIC MOVES
9.4.3. SCOT ANALYSIS
9.5. SHIONOGI & CO., LTD.
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. STRATEGIC MOVES
9.5.4. SCOT ANALYSIS
9.6. ALLERGAN PLC
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. STRATEGIC MOVES
9.6.4. SCOT ANALYSIS
9.7. NEKTAR THERAPEUTICS
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. STRATEGIC MOVES
9.7.4. SCOT ANALYSIS
9.8. PURDUE PHARMA L.P.
9.8.1. OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. STRATEGIC MOVES
9.8.4. SCOT ANALYSIS
9.9. S.L.A. PHARMA AG
9.9.1. OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. SCOT ANALYSIS
9.10. MUNDIPHARMA INTERNATIONAL LIMITED
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. STRATEGIC MOVES
9.10.4. SCOT ANALYSIS
9.11. ONO PHARMACEUTICAL CO., LTD.
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. STRATEGIC MOVES
9.11.4. SCOT ANALYSIS
9.12. TAKEDA PHARMACEUTICAL COMPANY LIMITED
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. STRATEGIC MOVES
9.12.4. SCOT ANALYSIS
9.13. THERAVANCE BIOPHARMA INC
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. STRATEGIC MOVES
9.13.4. SCOT ANALYSIS
9.14. VALEANT PHARMACEUTICALS INTERNATIONAL
9.14.1. OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. STRATEGIC MOVES
9.14.4. SCOT ANALYSIS
9.15. COSMO PHARMACEUTICALS SA
9.15.1. OVERVIEW
9.15.2. PRODUCT PORTFOLIO
9.15.3. STRATEGIC MOVES
9.15.4. SCOT ANALYSIS
9.16. DAEWOONG PHARMACEUTICAL CO., LTD.
9.16.1. OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. STRATEGIC MOVES
9.16.4. SCOT ANALYSIS
9.17. C.B. FLEET COMPANY, INC.
9.17.1. OVERVIEW
9.17.2. PRODUCT PORTFOLIO
9.17.3. STRATEGIC MOVES
9.17.4. SCOT ANALYSIS
LIST OF TABLES
TABLE 1 NORTH AMERICA OIC DRUG MARKET BY COUNTRIES 2017-2025 ($ MILLION)
TABLE 2 PHARMACOLOGICAL APPROACHES TO TREAT OPIOID INDUCED CONSTIPATION
TABLE 3 LAXATIVES USED FOR OPIOID INDUCED CONSTIPATION
TABLE 4 SIDE EFFECTS OF USING LAXATIVES
TABLE 5 PATIENTS UNFIT FOR INTAKE OF OPIOIDS
TABLE 6 NORTH AMERICA OIC DRUG MARKET BY DRUG TYPE, 2017-2025 ($ MILLION)
TABLE 7 PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)
TABLE 8 PRODUCT PROFILE (LUBIPROSTONE)
TABLE 9 PRODUCT PROFILE (NALOXEGOL)
TABLE 10 PIPELINE PRODUCT PROFILE (NALDEMEDINE)
TABLE 11 PIPELINE PRODUCT PROFILE (ALVIMOPAN, DOLCANATIDE)
TABLE 12 PIPELINE PRODUCT PROFILE (ELOBIXIBAT)
TABLE 13 NORTH AMERICA OIC DRUG MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
TABLE 14 PRODUCT PROFILE (LUBIPROSTONE)
TABLE 15 NORTH AMERICA PRESCRIBED OIC DRUGS MARKET 2017-2025($ MILLION)
TABLE 16 PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)
TABLE 17 PRODUCT PROFILE (METAMUCIL)
TABLE 18 PRODUCT PROFILE (BISACODYL)
TABLE 19 NORTH AMERICA OIC DRUGS MARKET BY COUNTRY, 2017-2025($ MILLION)
TABLE 1 NORTH AMERICA OIC DRUG MARKET BY COUNTRIES 2017-2025 ($ MILLION)
TABLE 2 PHARMACOLOGICAL APPROACHES TO TREAT OPIOID INDUCED CONSTIPATION
TABLE 3 LAXATIVES USED FOR OPIOID INDUCED CONSTIPATION
TABLE 4 SIDE EFFECTS OF USING LAXATIVES
TABLE 5 PATIENTS UNFIT FOR INTAKE OF OPIOIDS
TABLE 6 NORTH AMERICA OIC DRUG MARKET BY DRUG TYPE, 2017-2025 ($ MILLION)
TABLE 7 PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)
TABLE 8 PRODUCT PROFILE (LUBIPROSTONE)
TABLE 9 PRODUCT PROFILE (NALOXEGOL)
TABLE 10 PIPELINE PRODUCT PROFILE (NALDEMEDINE)
TABLE 11 PIPELINE PRODUCT PROFILE (ALVIMOPAN, DOLCANATIDE)
TABLE 12 PIPELINE PRODUCT PROFILE (ELOBIXIBAT)
TABLE 13 NORTH AMERICA OIC DRUG MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
TABLE 14 PRODUCT PROFILE (LUBIPROSTONE)
TABLE 15 NORTH AMERICA PRESCRIBED OIC DRUGS MARKET 2017-2025($ MILLION)
TABLE 16 PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)
TABLE 17 PRODUCT PROFILE (METAMUCIL)
TABLE 18 PRODUCT PROFILE (BISACODYL)
TABLE 19 NORTH AMERICA OIC DRUGS MARKET BY COUNTRY, 2017-2025($ MILLION)
LIST OF FIGURES
FIGURE 1 NORTH AMERICA OIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 2 NORTH AMERICA OIC DRUG MARKET BY DRUG TYPE 2016 AND 2025 (%)
FIGURE 3 NORTH AMERICA OIC DRUG MARKET BY PRESCRIPTION TYPE 2016 (%)
FIGURE 4 INCREASING NUMBER OF OPIOID PRESCRIPTION ($ MILLION)
FIGURE 5 REASONS FOR THE GROWTH OF OPIOID MARKET.
FIGURE 6 THERAPEUTIC OPIOID USE IN US (G/100,000 POPULATION)
FIGURE 7 COMMON SIDE EFFECTS OF MOVANTIK
FIGURE 8 MAJOR USAGE OF OPIOIDS
FIGURE 9 CONSIDERATIONS TAKEN WHILE THE OPIOID USAGE
FIGURE 10 NORTH AMERICA METHYL NALTREXONE BROMIDE OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 11 NORTH AMERICA LUBIPROSTONE OIC DRUG MARKET 2017-2025 ($MILLION)
FIGURE 12 NORTH AMERICA NALOXEGOL OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 13 NORTH AMERICA PRESCRIBED OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 14 NORTH AMERICA PRESCRIBED BRANDED OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 15 NORTH AMERICA PRESCRIBED GENERIC OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 16 NORTH AMERICA OVER THE COUNTER OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 17 NORTH AMERICA OIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 18 US OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 19 CANADA OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 20 NUMBER OF PRESCRIPTIONS DISPENSED FOR OPIOIDS
FIGURE 1 NORTH AMERICA OIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 2 NORTH AMERICA OIC DRUG MARKET BY DRUG TYPE 2016 AND 2025 (%)
FIGURE 3 NORTH AMERICA OIC DRUG MARKET BY PRESCRIPTION TYPE 2016 (%)
FIGURE 4 INCREASING NUMBER OF OPIOID PRESCRIPTION ($ MILLION)
FIGURE 5 REASONS FOR THE GROWTH OF OPIOID MARKET.
FIGURE 6 THERAPEUTIC OPIOID USE IN US (G/100,000 POPULATION)
FIGURE 7 COMMON SIDE EFFECTS OF MOVANTIK
FIGURE 8 MAJOR USAGE OF OPIOIDS
FIGURE 9 CONSIDERATIONS TAKEN WHILE THE OPIOID USAGE
FIGURE 10 NORTH AMERICA METHYL NALTREXONE BROMIDE OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 11 NORTH AMERICA LUBIPROSTONE OIC DRUG MARKET 2017-2025 ($MILLION)
FIGURE 12 NORTH AMERICA NALOXEGOL OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 13 NORTH AMERICA PRESCRIBED OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 14 NORTH AMERICA PRESCRIBED BRANDED OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 15 NORTH AMERICA PRESCRIBED GENERIC OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 16 NORTH AMERICA OVER THE COUNTER OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 17 NORTH AMERICA OIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 18 US OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 19 CANADA OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 20 NUMBER OF PRESCRIPTIONS DISPENSED FOR OPIOIDS
